Literature DB >> 30123852

Dravet Syndrome: A Sodium Channel Interneuronopathy.

William A Catterall1.   

Abstract

Dravet Syndrome is a devastating childhood epilepsy disorder with high incidence of premature death plus comorbidities of ataxia, circadian rhythm disorder, impaired sleep quality, autistic-like social-interaction deficits and severe cognitive impairment. It is primarily caused by heterozygous loss-of-function mutations in the SCN1A gene that encodes brain voltage-gated sodium channel type-1, termed NaV1.1. Here I review experiments on mouse genetic models that implicate specific loss of sodium currents and action potential firing in GABAergic inhibitory interneurons as the fundamental cause of Dravet Syndrome. The resulting imbalance of excitatory to inhibitory neurotransmission in neural circuits causes both epilepsy and co-morbidities. Promising therapeutic approaches involving atypical sodium channel blockers, novel drug combinations, and cannabidiol give hope for improved outcomes for Dravet Syndrome patients.

Entities:  

Keywords:  Epilepsy; autism; cognitive deficit; interneurons; sodium channels

Year:  2017        PMID: 30123852      PMCID: PMC6091224          DOI: 10.1016/j.cophys.2017.12.007

Source DB:  PubMed          Journal:  Curr Opin Physiol        ISSN: 2468-8673


  45 in total

1.  Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

Authors:  Orrin Devinsky; J Helen Cross; Linda Laux; Eric Marsh; Ian Miller; Rima Nabbout; Ingrid E Scheffer; Elizabeth A Thiele; Stephen Wright
Journal:  N Engl J Med       Date:  2017-05-25       Impact factor: 91.245

2.  Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy.

Authors:  Frank H Yu; Massimo Mantegazza; Ruth E Westenbroek; Carol A Robbins; Franck Kalume; Kimberly A Burton; William J Spain; G Stanley McKnight; Todd Scheuer; William A Catterall
Journal:  Nat Neurosci       Date:  2006-08-20       Impact factor: 24.884

Review 3.  The core Dravet syndrome phenotype.

Authors:  Charlotte Dravet
Journal:  Epilepsia       Date:  2011-04       Impact factor: 5.864

4.  Dissecting the phenotypes of Dravet syndrome by gene deletion.

Authors:  Moran Rubinstein; Sung Han; Chao Tai; Ruth E Westenbroek; Avery Hunker; Todd Scheuer; William A Catterall
Journal:  Brain       Date:  2015-05-27       Impact factor: 13.501

5.  Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome.

Authors:  John C Oakley; Alvin R Cho; Christine S Cheah; Todd Scheuer; William A Catterall
Journal:  J Pharmacol Exp Ther       Date:  2013-02-19       Impact factor: 4.030

6.  Sudden unexpected death in a mouse model of Dravet syndrome.

Authors:  Franck Kalume; Ruth E Westenbroek; Christine S Cheah; Frank H Yu; John C Oakley; Todd Scheuer; William A Catterall
Journal:  J Clin Invest       Date:  2013-03-25       Impact factor: 14.808

7.  Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome.

Authors:  Moran Rubinstein; Ruth E Westenbroek; Frank H Yu; Christina J Jones; Todd Scheuer; William A Catterall
Journal:  Neurobiol Dis       Date:  2014-10-02       Impact factor: 5.996

8.  Fine Mapping of a Dravet Syndrome Modifier Locus on Mouse Chromosome 5 and Candidate Gene Analysis by RNA-Seq.

Authors:  Nicole A Hawkins; Nicole J Zachwieja; Alison R Miller; Lyndsey L Anderson; Jennifer A Kearney
Journal:  PLoS Genet       Date:  2016-10-21       Impact factor: 5.917

9.  Unexpected Efficacy of a Novel Sodium Channel Modulator in Dravet Syndrome.

Authors:  Lyndsey L Anderson; Nicole A Hawkins; Christopher H Thompson; Jennifer A Kearney; Alfred L George
Journal:  Sci Rep       Date:  2017-05-10       Impact factor: 4.379

10.  Tiagabine: efficacy and safety in partial seizures - current status.

Authors:  Jürgen Bauer; Déirdre Cooper-Mahkorn
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

View more
  28 in total

1.  Electrophysiological Alterations of Pyramidal Cells and Interneurons of the CA1 Region of the Hippocampus in a Novel Mouse Model of Dravet Syndrome.

Authors:  David A Dyment; Sarah C Schock; Kristen Deloughery; Minh Hieu Tran; Kerstin Ure; Lauryl M J Nutter; Amie Creighton; Julie Yuan; Umberto Banderali; Tanya Comas; Ewa Baumann; Anna Jezierski; Kym M Boycott; Alex E Mackenzie; Marzia Martina
Journal:  Genetics       Date:  2020-06-17       Impact factor: 4.562

2.  Interneuron Desynchronization Precedes Seizures in a Mouse Model of Dravet Syndrome.

Authors:  Conny H Tran; Michael Vaiana; Johan Nakuci; Ala Somarowthu; Kevin M Goff; Nitsan Goldstein; Priya Murthy; Sarah F Muldoon; Ethan M Goldberg
Journal:  J Neurosci       Date:  2020-02-26       Impact factor: 6.167

3.  Hippocampal deletion of NaV1.1 channels in mice causes thermal seizures and cognitive deficit characteristic of Dravet Syndrome.

Authors:  Rachael E Stein; Joshua S Kaplan; Jin Li; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

4.  Circadian regulation of sleep in a pre-clinical model of Dravet syndrome: dynamics of sleep stage and siesta re-entrainment.

Authors:  Raymond E A Sanchez; Ivana L Bussi; Miriam Ben-Hamo; Carlos S Caldart; William A Catterall; Horacio O De La Iglesia
Journal:  Sleep       Date:  2019-12-24       Impact factor: 5.849

Review 5.  Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?

Authors:  Meir Bialer; Emilio Perucca
Journal:  CNS Drugs       Date:  2022-01-30       Impact factor: 5.749

6.  Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy.

Authors:  Andrea Merseburg; Jacquelin Kasemir; Eric W Buss; Felix Leroy; Tobias Bock; Alessandro Porro; Anastasia Barnett; Simon E Tröder; Birgit Engeland; Malte Stockebrand; Anna Moroni; Steven A Siegelbaum; Dirk Isbrandt; Bina Santoro
Journal:  Elife       Date:  2022-08-16       Impact factor: 8.713

7.  Selective inhibition of gamma aminobutyric acid release from mouse hippocampal interneurone subtypes by the volatile anaesthetic isoflurane.

Authors:  Iris A Speigel; Hugh C Hemmings
Journal:  Br J Anaesth       Date:  2021-08-10       Impact factor: 11.719

Review 8.  Dravet Syndrome: Novel Approaches for the Most Common Genetic Epilepsy.

Authors:  Lori L Isom; Kelly G Knupp
Journal:  Neurotherapeutics       Date:  2021-08-10       Impact factor: 6.088

Review 9.  The Promising Epigenetic Regulators for Refractory Epilepsy: An Adventurous Road Ahead.

Authors:  Vemparthan Suvekbala; Haribaskar Ramachandran; Alaguraj Veluchamy; Mariano A Bruno Mascarenhas; Tharmarajan Ramprasath; M K C Nair; Venkata Naga Srikanth Garikipati; Rohit Gundamaraju; Ramasamy Subbiah
Journal:  Neuromolecular Med       Date:  2022-09-24       Impact factor: 4.103

10.  Human KCNQ5 de novo mutations underlie epilepsy and intellectual disability.

Authors:  Aguan D Wei; Paul Wakenight; Theresa A Zwingman; Angela M Bard; Nikhil Sahai; Marjolein H Willemsen; Helenius J Schelhaas; Alexander P A Stegmann; Judith S Verhoeven; Stella A de Man; Marja W Wessels; Tjitske Kleefstra; Deepali N Shinde; Katherine L Helbig; Alice Basinger; Victoria F Wagner; David Rodriguez-Buritica; Emily Bryant; John J Millichap; Kathleen J Millen; William B Dobyns; Jan-Marino Ramirez; Franck K Kalume
Journal:  J Neurophysiol       Date:  2022-05-18       Impact factor: 2.974

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.